MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics
MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced todaythat it has entered into a Catalyze agreement with EliLillyand Company (Lilly) toadvance anext-generationtherapeuticfor obesity. https://mma.prnewswire.com/media/2847314/medi_gene__signature_A_re_size_01.jpg MEDI&GENE's discovery platformis designed to unlock novel therapeutic pathways that have the potential to sustain long-term weight maintenance, lean mass maintenance, and durability of desired metabolic effects. Undertheagreement,Lilly ExploR&D […]